Efektivitas Pemberian Metformin terhadap Perbaikan Manifestasi Klinis pada Pasien Sindrom Polikistik Ovarium
Abstract
Abstract. Polycystic Ovarian Syndrome (PCOS) is a common endocrine disorder characterized by ovulatory dysfunction, hyperandrogenism, and the presence of polycystic ovaries. Metformin, which is an insulin sensitizer agent, is the most widely used therapy in the management of PCOS. This research aims to explore and analyze articles discussing the effectiveness of metformin in improving clinical manifestations in polycystic ovarian syndrome patients. This research is a Scoping Review of articles published in 2012-2022 from the Pubmed, Springer Link, ScienceDirect, and Taylor and Francis databases that meet the criteria of Population (women with PCOS), Intervention (administration of metformin), Comparison (therapy other than metformin), Outcome (improvement of ovarian dysfunction and size of polycystic features, improved fertility, reduced body weight, reduced insulin resistance, improved menstrual cycle, hyperinsulinemia, hyperandrogenism, and abnormal metabolic disorders), Study (randomized controlled trials). The PRISMA diagram method was used in this research. From the four databases, 7,389 articles were obtained, which were then screened according to the inclusion criteria, feasibility test, and critical review according to the Joanna Briggs Institute checklist, resulting in 11 articles. Based on the results of the analysis of 11 articles, 10 articles stated that single metformin therapy was superior in reducing BMI, waist circumference, blood glucose, HOMA index, and improving the menstrual cycle compared to myoinositol therapy, rosiglitazone, letrozole, oral contraceptive pills, clomiphene citrate, cupping fennel seeds, and ovaries. There is 1 article that states that metformin therapy can improve ovulatory dysfunction.
Abstrak. Polycystic Ovarian Syndrome (PCOS) merupakan gangguan endokrin umum yang ditandai dengan disfungsi ovulasi, hiperandrogen, dan adanya polikistik pada ovarium. Metformin merupakan agen sensitizer insulin adalah terapi yang paling banyak digunakan dalam penatalaksanaan PCOS. Tujuan dari penelitian adalah untuk mengeksplorasi dan menganalisis artikel yang membahas efektivitas metformin terhadap perbaikan manisfestasi klinis pada pasien polycystic ovarian syndrome. Penelitian ini merupakan Scoping Review artikel yang terbit tahun 2012-2022 dari database Pubmed, Springer Link, SienceDirect, dan Taylor and Francis yang sesuai dengan kriteria dengan Population (wanita penderita PCOS), Intervention (pemberian metformin), Comparison (terapi selain metformin), Outcome (perbaikan disfungsi ovarium dan ukuran gambaran polikistik, perbaikan fertilitas, menurunkan berat badan, mengurangi resistensi insulin, memperbaiki siklus menstruasi, hyperinsulinemia, hiperandrogenisme, dan kelainan metabolisme abnormal), Study (randomized controlled trials). Metode diagram PRISMA digunakan dalam penelitian ini, dari keempat database didapat 7,389 artikel yang kemudian dilakukan skrinning sesuai dengan kriteria inklusi, uji kelayakan, dan telaah kritis sesuai dengan checklist Joanna Briggs Institute dihasilkan 11 artikel. Berdasarkan hasil analisis dari 11 artikel terdapat 10 artikel yang menyatakan bahwa terapi metformin tunggal lebih unggul dalam menurunkan BMI, lingkar pinggang, glukosa darah, HOMA indeks, dan memperbaiki siklus menstruasi dibandingkan dengan terapi myoinositol, rosiglitazone, letrozole, pil kontrasepsi oral, clomiphene citrate, bekam biji adas dan ovarium. Terdapat 1 artikel yang menyatakan bahwa terapi metformin dapat memperbaiki disfungsi ovulasi.
References
Wong TY, Cheung CMG, Larsen M, Sharma S, Simó R. Erratum: Diabetic retinopathy. Nature Reviews Disease Primers. 2016;2(1):1-1.
Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril. Jan 2004;81(1):19-25.
Teede HJ, Misso ML, Costello MF, et al. Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Human reproduction. 2018;33(9):1602-1618.
Santoso B. Sindroma Ovarium Polikistik: Problem Reproduksi dan Tantangannya Terkait Dengan Gaya Hidup Perempuan Indonesia. 2014.
Morley LC, Tang T, Yasmin E, Norman RJ, Balen AH. Insulin‐sensitising drugs (metformin, rosiglitazone, pioglitazone, D‐chiro‐inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility. Cochrane Database of Systematic Reviews. 2017(11).
Sam S, Ehrmann DA. Metformin therapy for the reproductive and metabolic consequences of polycystic ovary syndrome. Diabetologia. 2017;60(9):1656-1661.
Rababa'h AM, Matani BR, Ababneh MA. The ameliorative effects of marjoram in dehydroepiandrosterone induced polycystic ovary syndrome in rats. Life sciences. 2020;261:118353.
Artini PG, Obino MER, Sergiampietri C, et al. PCOS and pregnancy: a review of available therapies to improve the outcome of pregnancy in women with polycystic ovary syndrome. Expert review of endocrinology & metabolism. 2018;13(2):87-98.
Jelodar G, Masoomi S, Rahmanifar F. Hydroalcoholic extract of flaxseed improves polycystic ovary syndrome in a rat model. Iranian journal of basic medical sciences. 2018;21(6):645.
Azziz R, Carmina E, Dewailly D, et al. Criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an androgen excess society guideline. The Journal of Clinical Endocrinology & Metabolism. 2006;91(11):4237-4245.
Hajimonfarednejad M, Nimrouzi M, Heydari M, Zarshenas MM, Raee MJ, Jahromi BN. Insulin resistance improvement by cinnamon powder in polycystic ovary syndrome: A randomized double‐blind placebo controlled clinical trial. Phytotherapy Research. 2018;32(2):276-283.
Li Y, Tan J, Wang Q, Duan C, Hu Y, Huang W. Comparing the individual effects of metformin and rosiglitazone and their combination in obese women with polycystic ovary syndrome: a randomized controlled trial. Fertil Steril. Jan 2020;113(1):197-204.
El-Sharkawy AA, Abdelmotaleb GS, Aly MK, Kabel AM. Effect of metformin on sleep disorders in adolescent girls with polycystic ovarian syndrome. Journal of pediatric and adolescent gynecology. 2014;27(6):347-352.
Rizky M, 1 H. Uji Aktivitas Sitotoksik Ekstrak Etanol Daun Sirsak (Annona Muricata L.) yang Tumbuh di Daerah Cianjur Menggunakan Metode Brine Shirmp Lethality Test (BSLT) [Internet]. Vol. 1. 2023. Available from: https://journal.sbpublisher.com/index.php/pharmacomedic
Tagliaferri V, Romualdi D, Immediata V, et al. Metformin vs myoinositol: which is better in obese polycystic ovary syndrome patients? A randomized controlled crossover study. Clin Endocrinol (Oxf). May 2017;86(5):725-730.
Tao T, Zhang Y, Zhu YC, et al. Exenatide, Metformin, or Both for Prediabetes in PCOS: A Randomized, Open-label, Parallel-group Controlled Study. J Clin Endocrinol Metab. Mar 8 2021;106(3):e1420-e1432.
Al-Zubeidi H, Klein KO. Randomized clinical trial evaluating metformin versus oral contraceptive pills in the treatment of adolescents with polycystic ovarian syndrome. J Pediatr Endocrinol Metab. Jul 2015;28(7-8):853-858.
Shokrpour M, Foroozanfard F, Afshar Ebrahimi F, et al. Comparison of myo-inositol and metformin on glycemic control, lipid profiles, and gene expression related to insulin and lipid metabolism in women with polycystic ovary syndrome: a randomized controlled clinical trial. Gynecological Endocrinology. 2019;35(5):406-411.
Abd Elgafor I. Efficacy of combined metformin-letrozole in comparison with bilateral ovarian drilling in clomiphene-resistant infertile women with polycystic ovarian syndrome. Arch Gynecol Obstet. Jul 2013;288(1):119-123.
Tiwari N, Pasrija S, Jain S. Randomised controlled trial to study the efficacy of exercise with and without metformin on women with polycystic ovary syndrome. Eur J Obstet Gynecol Reprod Biol. Mar 2019;234:149-154.
Mokaberinejad R, Rampisheh Z, Aliasl J, Akhtari E. The comparison of fennel infusion plus dry cupping versus metformin in management of oligomenorrhoea in patients with polycystic ovary syndrome: a randomised clinical trial. J Obstet Gynaecol. Jul 2019;39(5):652-658.
